TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein Sells 4,000 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 4,000 shares of the stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $95.12, for a total transaction of $380,480.00. Following the completion of the transaction, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,047,155.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

TransMedics Group Stock Down 0.7 %

TMDX stock opened at $87.24 on Friday. The firm has a fifty day moving average price of $82.97 and a 200 day moving average price of $72.98. TransMedics Group, Inc. has a fifty-two week low of $36.42 and a fifty-two week high of $99.63. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.22. The firm had revenue of $81.20 million during the quarter, compared to analyst estimates of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. TransMedics Group’s revenue for the quarter was up 158.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.21) earnings per share. Sell-side analysts forecast that TransMedics Group, Inc. will post -0.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Morgan Stanley raised their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. raised their target price on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Piper Sandler assumed coverage on shares of TransMedics Group in a research note on Thursday, March 28th. They set an “overweight” rating and a $95.00 target price on the stock. Finally, Oppenheimer raised their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 27th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $102.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Ancora Advisors LLC purchased a new position in TransMedics Group during the first quarter worth $38,000. First Horizon Advisors Inc. boosted its stake in TransMedics Group by 45.1% during the first quarter. First Horizon Advisors Inc. now owns 544 shares of the company’s stock worth $41,000 after buying an additional 169 shares during the period. Belpointe Asset Management LLC boosted its stake in TransMedics Group by 51.6% during the first quarter. Belpointe Asset Management LLC now owns 558 shares of the company’s stock worth $42,000 after buying an additional 190 shares during the period. PNC Financial Services Group Inc. boosted its stake in TransMedics Group by 595.3% during the second quarter. PNC Financial Services Group Inc. now owns 598 shares of the company’s stock worth $50,000 after buying an additional 512 shares during the period. Finally, Point72 Hong Kong Ltd purchased a new position in TransMedics Group during the fourth quarter worth $47,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.